Evotec SE (NASDAQ:EVO – Get Free Report)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $4.30, but opened at $4.10. Evotec shares last traded at $4.09, with a volume of 94,091 shares.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a “sell” rating to a “hold” rating in a report on Thursday, April 24th.
Get Our Latest Stock Analysis on EVO
Evotec Stock Down 3.2%
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. DCF Advisers LLC raised its position in Evotec by 227.0% in the first quarter. DCF Advisers LLC now owns 751,579 shares of the company’s stock worth $2,510,000 after acquiring an additional 521,708 shares during the period. ABC Arbitrage SA bought a new stake in Evotec in the first quarter worth about $260,000. Lighthouse Investment Partners LLC bought a new stake in Evotec in the fourth quarter worth about $166,000. CSS LLC IL bought a new stake in Evotec in the fourth quarter worth about $50,000. Finally, Bank of America Corp DE raised its position in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after acquiring an additional 9,289 shares during the period. 5.81% of the stock is currently owned by institutional investors and hedge funds.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.
See Also
- Five stocks we like better than Evotec
- Industrial Products Stocks Investing
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- Buy P&G Now, Before It Sets A New All-Time High
- Here’s Why Call Option Traders Love Dutch Bros Stock
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.